Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment: study protocol for a phase II, multicentre, non-randomised study

Fumiyuki Yamasaki,Shinichiro Koizumi,Tomoyuki Shimabukuro ,Hiroaki Nagashima,Tomoyuki Akita,Yoshihiro Tsukamoto,Kazuhiro Tanaka,Hirotaka Fudaba,Yukari Kawasaki,Kentaro Fujii,Takafumi Nishizaki,Makoto Ideguchi,Kazuhiko Kurozumi,Katsuhisa Taguchi ,Kenji Yoshida,Kazuhiko Sakamoto ,Tomohiro Hosoya,Kosuke Katayama,Takashi Sasayama,Noriyuki Nakayama,Kenichiro Asano,Ikuno Nishibuchi,Manabu Natsumeda,Ushio Yonezawa,Kiyohide Kakuta,Momii Yasutomo,Atsushi Kambe

doi:10.1136/bmjopen-2022-071350

Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment: study protocol for a phase II, multicentre, non-randomised study

Fumiyuki Yamasaki, Shinichiro Koizumi + Show 25 more

Open Access

https://doi.org/10.1136/bmjopen-2022-071350

Copy DOI

Journal: BMJ open	Publication Date: Apr 1, 2023
Citations: 1	License type: open-access

Affiliation: Hiroshima University, Hamamatsu University School of Medicine, Ube (Japan), Kobe University, Hiroshima University Hospital, Niigata University, Oita University, Okayama University, National Sanyo Hospital, Tottori University Hospital, Tottori University, Hirosaki University, Gifu University

#Primary Central Nervous System Lymphoma #Geriatric 8 + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

IntroductionMultidrug chemoimmunotherapy with rituximab, high-dose methotrexate, procarbazine and vincristine (R-MPV) is a standard therapy for younger patients with primary central nervous system lymphoma (PCNSL); however, prospective data regarding its use...

Full Text